3 Firms Usher Radius Health Off Public Market In $890M Deal

Investment firms Gurnet Point Capital and Patient Square Capital will acquire publicly traded biopharmaceutical company Radius Health Inc. in a transaction valued up to $890 million and put together by Kirkland...

Already a subscriber? Click here to view full article